JANUARY 2020 APPIRED III – 9 INTERNATIONAL CENTRES AND MORE TO COME

Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients

www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today

RESCAP® IN SEVERE BURN WOUND TRIAL

Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall

JANUARY 2020 APPIRED III – 9 INTERNATIONAL CENTRES AND MORE TO COME

APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,

CLINICAL DATA APPIRED I AND APPIRED II ARE BASIS FOR BREAKTHROUGH

Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the

JANUARY 2020 APPIRED III – 9 INTERNATIONAL CENTRES AND MORE TO COME

News and Updates

Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients

RESCAP® IN SEVERE BURN WOUND TRIAL

JANUARY 2020 APPIRED III – 9 INTERNATIONAL CENTRES AND MORE TO COME

CLINICAL DATA APPIRED I AND APPIRED II ARE BASIS FOR BREAKTHROUGH

Invest in Alloksys

Subscribe to our NewsLetter!

Quick Links

Other Links

Contact Info

AgroBusiness Park 10, 6708 PW, Wageningen, the Netherlands

+31 (0)317 466 260